BeStock  
Stocks › IMNM

Immunome IMNM

US equityMarket cap rank #2622Biotechnology
$21.17 +$0.27 (+1.29%)
Pre-market · Oct 6, 7:40 am ET · After hours $21.31 +0.66%
Open$20.79
Prev close$20.90
Day range$20.67 – $21.48
Volume1.22M
Market cap$2.50B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00-100.0% YoY
Operating profit-$78.14M-68.1% YoY
Net profit-$73.13M-68.5% YoY
Diluted EPS-$0.65-30.0% YoY

Revenue, last 8 quarters

$2.9MSep '24$2.7MDec '24$2.9MMar '25$4.0MJun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-47.1MSep '24$-80.2MDec '24$-41.6MMar '25$-43.4MJun '25$-57.5MSep '25$-69.9MDec '25$-53.8MMar '26$-73.1MJun '26

Diluted EPS by quarter

-0.78Sep '24-1.28Dec '24-0.52Mar '25-0.50Jun '25-0.65Sep '25-0.75Dec '25-0.48Mar '26-0.65Jun '26

Profitability & balance sheet

Liabilities / assets7.1%
Cash & investments$520.00M
Total debt$4.59M
Net cash (debt)$515.41M

Income statement

Line item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Net Income to Common Stockholders -$73.13M -$53.84M -$69.90M -$57.46M -$43.40M
Net Income to Parent Company -$73.13M -$53.84M -$69.90M -$57.46M -$43.40M
Profit from Continuing Operations -$73.13M -$53.84M -$69.90M -$57.46M -$43.40M
Net Profit -$73.13M -$53.84M -$69.90M -$57.46M -$43.40M
Pretax Profit -$73.13M -$53.84M -$69.90M -$57.46M -$43.40M
Non-Operating Interest Income $5.01M $5.49M $2.96M $2.68M $3.08M
Diluted EPS -$0.65 -$0.48 -$0.75 -$0.65 -$0.50
Basic EPS -$0.65 -$0.48 -$0.75 -$0.65 -$0.50
Total Revenue as Reported $0.00 $0.00 $0.00 $0.00 $4.02M
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $4.02M
Operating Expense $78.14M $59.33M $72.86M $60.14M $50.49M
Selling and Admin Expenses $18.25M $12.95M $12.09M $10.95M $10.04M
-General & Admin Expense $18.25M $12.95M $12.09M $10.95M $10.04M
Net Non-Operating Interest Income (Expense) $5.01M $5.49M $2.96M $2.68M $3.08M
Operating Profit -$78.14M -$59.33M -$72.86M -$60.14M -$46.48M
Research & Development $59.89M $46.38M $60.77M $49.19M $40.45M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Total Current Liabilities $35.71M $27.41M $44.99M $31.45M $22.88M
Payables $6.00M $5.53M $3.34M $6.15M $4.66M
-Accounts Payable $6.00M $5.53M $3.34M $6.15M $4.66M
Current Accrued Expenses $20.17M $15.64M $26.50M $16.39M $11.40M
Short-Term Debt and Capital Lease Obligation $152,000.00 – – – –
-Current Capital Lease Obligation $152,000.00 – $0.00 $0.00 $0.00
Other Current Liabilities $3.23M $3.18M $3.63M $1.74M $1.17M
Total Non-Current Liabilities $4.59M $3.69M $3.86M $4.01M $4.14M
Long Term Debt and Capital Lease Obligation $4.59M $3.69M $3.86M $4.01M $4.14M
-Long Term Capital Lease Obligation $4.59M $3.69M $3.86M $4.01M $4.14M
Total Equity $525.08M $588.69M $634.34M $263.92M $269.27M
Stockholders' Equity $525.08M $588.69M $634.34M $263.92M $269.27M
Capital Stock $11,000.00 $11,000.00 $11,000.00 $9,000.00 $9,000.00
Total Liabilities $40.30M $31.11M $48.85M $35.46M $27.02M
Other Non-Current Assets $5.63M $5.57M $4.80M $4.77M $4.56M
Total Assets $565.38M $619.79M $683.19M $299.38M $296.29M
Total Current Assets $538.45M $594.31M $660.78M $279.92M $277.43M
Cash and Cash Equivalents & Short-Term Investments $520.00M $582.69M $653.48M $272.64M $268.04M
-Cash and Cash Equivalents $217.71M $582.69M $653.48M $272.64M $143.88M
-Short Term Investments $302.29M – $0.00 $0.00 $124.16M
Other Current Assets $18.45M $11.62M $7.30M $7.29M $9.40M
Total Non-Current Assets $26.94M $25.48M $22.41M $19.45M $18.86M
Net PPE $21.30M $19.91M $17.61M $14.69M $14.29M
-Gross PPE $21.30M $19.91M $23.98M $14.69M $14.29M
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $11,000.00 $11,000.00 $11,000.00 $9,000.00 $9,000.00
Additional Paid-In Capital $1.38B $1.37B $1.36B $922.17M $870.09M
Retained Earnings -$855.13M -$782.00M -$728.16M -$658.26M -$600.81M
Gains/Losses Not Affecting Retained Earnings -$333,000.00 – $0.00 $0.00 -$24,000.00
-Accumulated Depreciation – – -$6.37M – –
Current Deferred Liabilities – – $0.00 $0.00 $0.00

Cash flow

Line item 2025 ANNUAL 2024 ANNUAL 2023 ANNUAL 2022 ANNUAL 2021 ANNUAL
Proceeds from Stock Option Exercised $913,000.00 $5.76M $371,000.00 $32,000.00 $1.44M
Change in Working Capital -$15.23M $14.87M $12.00M $2.24M $2.78M
Other Non-Cash Items $10.00M $152.34M $80.80M – $4,000.00
Depreciation & Depletion & Amortization $2.96M $2.10M $728,000.00 $631,000.00 $755,000.00
Gain/Loss from Continuing Operations $896,000.00 – – – -$500,000.00
Net Income from Continuing Operations -$212.39M -$292.96M -$106.81M -$36.90M -$24.71M
Net cash flow from continuing operations -$190.92M -$110.79M -$7.57M -$28.69M -$18.23M
Operating Cash Flow -$190.92M -$110.79M -$7.57M -$28.69M -$18.23M
Free Cash Flow -$206.85M -$164.30M -$8.40M -$28.94M -$18.31M
Ending Cash Balance $653.69M $143.45M $98.78M $20.42M $49.33M
Net cash flow from investing $60.80M -$85.06M -$30.48M -$248,000.00 -$79,000.00
Net Other Financing Charges -$39.46M -$15.23M -$9.00M – -$781,000.00
-Change in Prepaid Assets -$3.49M $906,000.00 -$4.14M $5.07M -$4.28M
Net Common Stock Issuance $678.90M $250.00M $125.03M $0.00 $27.23M
Net Cash Flow from Continuing Financing Activities $640.36M $240.53M $116.41M $32,000.00 $27.77M
Financing Cash Flow $640.36M $240.53M $116.41M $32,000.00 $27.77M
Net Investment Purchase and Sale $76.73M -$31.56M -$38.93M $0.00 –
Net Intangibles Purchase and Sale -$6.25M -$46.34M $0.00 – –
Net PPE Purchase and Sale -$9.69M -$7.17M -$831,000.00 -$248,000.00 -$79,000.00
Net Cash Flow from Continuing Investing Activities $60.80M -$85.06M -$30.48M -$248,000.00 -$79,000.00
-Change In Other Working Capital -$6.94M -$9.04M $15.98M – –
-Change in Other Current Liabilities -$166,000.00 -$67,000.00 $153,000.00 -$229,000.00 $0.00
-Change in Payables and Accrued Expense -$4.63M $23.08M $6,000.00 -$2.60M $7.06M
Net Change in Cash $510.24M $44.67M $78.36M -$28.91M $9.46M
Beginning Cash Balance $143.45M $98.78M $20.42M $49.33M $39.87M
Net Business Purchase and Sale – – $9.28M $0.00 –
Net Issuance Payments Of Debt – – – – -$113,000.00

Discussion

No comments yet — be the first to weigh in on IMNM.

Leave a comment

Scroll to Top